Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Telehealth providers in New Jersey

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Telehealth prescribing is allowed in New Jersey, including asynchronous care. What New Jersey requires of telehealth prescribers and pharmacies, plus listings with their verification status.

New Jersey at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Telehealth providers serving New Jersey

Bodybuilding Peptides

Sponsored

Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.

Telehealth provider · 17 products · partner lists from $172 a month · Says it serves New Jersey (not yet confirmed)

  • Prescription only, no research-use-only sales
  • Public cancellation and refund policy

We may earn a commission from these links.

Telehealth prescribing rules in New Jersey

N.J.S.A. 45:1-61 through 45:1-66 (P.L.2017, c.117, as amended by P.L.2021, c.310, effective December 21, 2021) let a New Jersey-licensed health care provider establish a provider-patient relationship and treat through telemedicine, held to the in-person standard of care. As amended, N.J.S.A. 45:1-62(c) says telemedicine may be provided using interactive, real-time, two-way communication technologies or asynchronous store-and-forward technology. Store-and-forward may be used with or without real-time audio if, after reviewing the patient's medical records, the provider determines the in-person standard of care can be met and tells the patient so at the outset. Under N.J.S.A. 45:1-63, a proper relationship requires identifying the patient, disclosing the provider's credentials, reviewing the patient's history and records before an initial encounter, and determining before each encounter whether the in-person standard of care can be met by telemedicine. Unless that relationship exists, a provider may not prescribe based solely on responses to an online static questionnaire. The Board of Medical Examiners' rule N.J.A.C. 13:35-6B.5, adopted in 2020, still calls for real-time communication with video, but it predates the 2021 amendment, and this record treats the later statute as controlling. Schedule II prescribing by telemedicine generally requires an initial in-person exam, which does not apply to the non-controlled peptides in this database. This record classifies asynchronous prescribing as allowed because the amended statute expressly permits store-and-forward services without any real-time interaction. [2] [3] [4] [5] [9]

Compounded GLP-1 access in New Jersey

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Board's 2023 statement independently bars semaglutide salt forms and requires documented, FDA-registered sourcing of semaglutide base. [10] [13]

Research use only sellers in New Jersey

New Jersey's food and drug law (N.J.S.A. Title 24) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act limits dispensing to licensed pharmacies. The Board's semaglutide statement also warns pharmacies against non-pharmaceutical-grade ingredients. [6] [10] [11] [14]

How to check a telehealth provider in New Jersey

  1. Confirm the prescriber is licensed or registered to treat patients located in New Jersey; the telehealth rules above explain what New Jersey requires. [2] [3] [4] [5] [9]
  2. Ask which pharmacy will fill the prescription and check it in the New Jersey State Board of Pharmacy (Division of Consumer Affairs) license lookup. [1] [6] [7] [8] [10] [12]
  3. Get the full price in writing first: consult fees, membership fees, and the medication itself.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in New Jersey. [6] [10] [11] [14]

Sources

  1. [1]New Jersey State Board of Pharmacy (Division of Consumer Affairs)
  2. [2]N.J.S.A. 45:1-62, Provision of health care through use of telemedicine, telehealth; requirements for provider (Justia mirror, 2025 edition, as amended by P.L.2021, c.310; the official session law P.L.2021, c.310 is the primary source)
  3. [3]N.J.S.A. 45:1-63, Establishment of proper provider-patient relationship; exceptions (Justia mirror, 2025 edition)
  4. [4]New Jersey P.L.2017, c.117 (S291), Telemedicine and Telehealth Act
  5. [5]New Jersey P.L.2021, c.310 (S2559), amending the Telemedicine and Telehealth Act, approved December 21, 2021
  6. [6]New Jersey Pharmacy Practice Act, N.J.S.A. 45:14-40 and following, and N.J.A.C. 13:39 (Board laws and regulations)
  7. [7]N.J.S.A. 45:14-73, Registration of out-of-State pharmacies; requirements
  8. [8]N.J.A.C. 13:39-4.20, Out-of-State pharmacy registration
  9. [9]N.J.A.C. 13:35-6B.5, Provision of health care services through telemedicine or telehealth (Board of Medical Examiners)
  10. [10]New Jersey State Board of Pharmacy: Statement concerning semaglutide compounding (posted version dated November 6, 2023)